Health
Thu, Jun 13, 2019 11:42 AM

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
Health

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
Thu, Jun 13, 2019 11:42 AM
Author:
Thu, Jun 13, 2019 11:42 AM
Author:

The pegfilgrastim biosimilar is delivered subcutaneously to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).  Neutropenia refers to an abnormally low number of neutrophils (a type of white blood cell) which can increase the risk of life-threatening infections and is a common side effect of chemotherapy. The biosimilar product was approved in the European Union in November 2018.

This strategic deal expands patients’ access to pegfilgrastim therapy in four countries of Egis. With this agreement Egis gained the exclusive rights to introduce the biosimilar medicine in Hungary, Romania, Lithuania and Latvia.

#biosimilar #products #health
Related articles from Egis Magazine
Innovation

Egis' medicines won the Innovation Grand Prize
More
Events

Egis as a special partner at one of the biggest professional events of the year for pharmacists
More
Egis World

Egis receives accolade for supporting major health screening programme
More

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox